Latest Updates
-
60 Is the New 40, But Is Your Body Keeping Up? The Health Checks Seniors Shouldn't Skip -
Aasha Singh Jaiswal, India's First Female Mimicry Artist, Dies At 83 -
Setting Up A New Office? Vastu Expert Shares Common Mistakes To Avoid -
Who Is Kaziah Liz Mejo? Meet The 19-Year-Old Miss Universe India 2026 -
Saransh Jain Replaces Kuldeep Yadav: Everything To Know About India's New Debutant -
Fourth Shravan Somwar 2026: Why The Last Sawan Monday Is Considered So Special For Shiva Devotees -
Onam 2026: Kasavu Saree, But Make It Fashion-Forward With 7 Chic Styling Tricks -
From Biarritz Runway To Red Carpet: How Chanel’s Barefoot Heel Cap Became Fashion’s Latest Viral Controversy -
Partial Lunar Eclipse 2026: Raksha Bandhan Coincides With Rare Celestial Event, But Is It Visible In India? -
Tokyo Earthquake: 5.9-Magnitude Quake Shakes Japan, Leaves 37 Injured
Covid Vaccine Efficacy Limited Against Omicron, Says Study
People who are double-vaccinated and those who have recovered from infection by previous strains of the SARS-CoV-2 virus have virtually no antibody protection against the Omicron variant, according to a study.

The research, recently published in the journal Allergy, found that only individuals vaccinated with a third or booster dose of the Covid-19 vaccine form antibodies that can partially block Omicron. Researchers from the Medical University of Vienna examined an Austrian subpopulation of vaccinated and recovered individuals for their antibody status and protection against the Wuhan, Delta and Omicron variants.
They adapted for Omicron a test developed for the previous variants, which investigates whether the virus can bind to the receptor on human cells via its receptor-binding domain (RBD).
RBD is used by SARS-CoV-2 to enter human cells via the ACE2 receptor on cells.
The researchers also examined people who had received different vaccines and combinations currently licensed in Austria.
The findings show that both Covid-19 convalescent individuals and individuals who had been vaccinated twice developed antibody protection against Delta.
However, the antibodies were not able to block the receptor-binding domain against Omicron, the researchers said.
The study found that blockade of Omicron was better in those individuals who had received the third vaccination.
"The third vaccination developed protective antibodies in many individuals. However, there is also a significant proportion (20 per cent) in whom no protection was established," said Rudolf Valenta, who led the research team.
The RBD differed only slightly in all previously known SARS-CoV-2 variants so that infections with these and the currently available vaccines provided protection against the previous variants, the researchers said.
Omicron is the first variant that differs greatly from the previous variants in RBD. Consequently, infections with the previous variants and currently available vaccines provide little or no protection against Omicron, they said.
The researchers noted that the best protection would be to develop a broadly effective combination vaccine that protects against both the previous variants and Omicron.
"Until we have such a vaccine, only repeated vaccinations with the existing vaccines will provide some protection," Valenta said.
"The protective effect achieved by vaccination can be evaluated with special tests that can be rapidly adapted to new virus variants," the immunologist added.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications